{
    "nctId": "NCT00397215",
    "officialTitle": "Evaluate Immunogenicity & Safety of a Single or Double-dose of the Pandemic Influenza Candidate Vaccine (GSK1562902A) Given Following a Two-administration Schedule (21 Days Apart) in Adults Over 60 Yrs",
    "inclusionCriteria": "* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.\n* A male or female aged 61 years or above at the time of the first vaccination.\n* Written informed consent obtained from the subject.\n* Healthy subjects or subjects with well controlled underlying disease.\n* Must have minimum age of 60 Years",
    "exclusionCriteria": "* Administration of the licensed MF59-containing vaccines, e.g. Fluad\u2122 or Addigrip\u2122 or virosome-based influenza vaccines such as Inflexal V\u2122, InfectoVac Flu\u2122 or Invivac\u2122 during the 2006-2007 influenza season.\n* Administration of licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study.\n* Planned administration of a vaccine not foreseen by the study protocol up to 30 days after the second vaccination with H5N1 vaccine.\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first administration of the study vaccine.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).\n* History of chronic alcohol consumption and/or drug abuse.\n* History of hypersensitivity to vaccines.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine (including egg and thiomersal allergy).\n* Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.\n* Acute disease at the time of enrolment.\n* Serious chronic disease including any medically significant chronic pulmonary, cardiovascular, renal, neurological, psychiatric or metabolic disorder, as determined by medical history and physical examination.\n* Administration of immunoglobulins and/or any blood products within the three months preceding the first vaccination or during the study.\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to the first vaccination, or planned use during the study period.\n* Any condition which, in the opinion of the investigator, prevents the subject from participation in the study."
}